Premium
Comparing E2‐sensitivity of classically responding genes, pS2 and PR in two breast cancer cell lines
Author(s) -
Fasano Jessica L.,
George Staicymol,
Dean Diane M.
Publication year - 2007
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.21.5.a297-c
Subject(s) - estrogen , etoposide , estrogen receptor , cell culture , efflux , messenger rna , biology , cancer research , cancer cell , gene , microbiology and biotechnology , drug resistance , breast cancer , cell , gene expression , cancer , endocrinology , chemotherapy , biochemistry , genetics
The MCF7/VP cell line is a chemotherapeutic resistant breast cancer cell line derived from the MCF7/WT cell line by chronic exposure to etoposide. The gene for the Multi‐drug Resistance Protein 1 (mrp1) is amplified in MCF7/VP cells. Multi‐drug Resistance Protein 1 is an ATP‐dependent drug efflux pump that has been linked to multi‐drug resistance in cancer. Previously, our lab found up‐regulation of mrp1 mRNA in response to estrogen‐treatment in MCF7/WT cells but not in MCF7/VP cells. The goal of this research was to determine the cause of this difference by measuring the response to estrogen‐treatment of two classically estrogen‐sensitive genes: pS2/TFF1 and the progesterone receptor (PR). The MCF7/WT and MCF7/VP cells were exposed to 17beta‐estradiol (10‐8M) for various amount of time (0.5hr to 24 hrs). We isolated total RNA using the Qiagen Rneasy@ kit and subjected it to quantitative real time RT‐PCR; thus, the levels of mRNA for pS2/TTF1 and PR were determined. Our preliminary data indicates that the MCF7/WT and MCF7/VP cells show a similar response to estrogen. Therefore, the previously observed difference in estrogen regulation of the mrp1 gene was due to amplification.